![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, February 2006, p. 788-790, Vol. 50, No. 2
0066-4804/06/$08.00+0 doi:10.1128/AAC.50.2.788-790.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Center for Anti-Infective Research and Development,1 Division of Infectious Diseases, Hartford Hospital, Hartford, Connecticut 06102,3 Theravance, Inc., South San Francisco, California 940802
Received 1 August 2005/ Returned for modification 20 August 2005/ Accepted 24 November 2005
 |
ABSTRACT |
|---|
 Top Abstract TextReferences |
|---|
|
TEXT |
|---|
|
TopAbstractTextReferences |
|---|
4 h) against S. aureus (3, 10). Currently, there are limited pharmacokinetic data available for telavancin, and no studies regarding the ability for telavancin to penetrate into skin structures have been published. The evaluation of drug concentrations by using the cantharidin-induced skin blister model attempts to mimic situations within an infected tissue compartment. Previous studies using this model have been successfully performed at our institution (9, 13). The primary objective of this study was to determine the steady-state pharmacokinetic profile of telavancin in plasma and blister fluid when telavancin is administered intravenously over one hour as 7.5 mg/kg of body weight every 24 h for a total of three doses. Safety was also assessed.
This study was approved by Hartford Hospital's Institutional Review Board. All subjects were given a detailed description of the study, and all provided written informed consent. Nine healthy subjects (eight males and one female) were enrolled in this single-center, open-label study. One male subject was withdrawn due to elevated serum transaminases and LDH levels, which were unrelated to study drug. Thus, only eight subjects completed the study. The subjects were 21 to 46 years of age (mean age, 23.9 years) and 134 to 252 lb in weight (mean weight, 176.7 lb). Participation included a screening evaluation within 3 weeks of drug administration on day 1 and a 5-day (4-night) inpatient period, with a follow-up visit 72 h after the last dose of study drug. Subjects were enrolled after the screening evaluation and laboratory evaluations (including hematologies, blood chemistries, and urinalyses) revealed no clinically significant abnormalities.
Each subject received a one-hour infusion of telavancin (Theravance, Inc., South San Fransisco, CA), at a dose of 7.5 mg/kg (based on subjects' weights on study day 0), every 24 h for a total of three doses. Subjects were allowed to consume a light meal approximately one hour prior to the start of the infusion. Water and fruit juice were allowed after the completion of the infusion, and food was allowed approximately 4 h following the completion of drug administration. No tobacco, alcohol, grapefruit juice, caffeinated tea, chocolate, or caffeinated coffee, or any other caffeine-containing product was permitted during the study.
Approximately 14 h prior to the start of the final dose of telavancin, six drops (each drop measuring 0.2 ml) of 0.25% cantharidin ointment made from cantharidin powder (Sigma Laboratories, St. Louis, MO) and standard ointment base were applied to the anterior forearms of the subjects to produce six skin blisters per subject. The seventh and final blister was induced using the same methodology as described above approximately 14 h prior to the final sample collection on study day 4.
Blood samples were collected from an indwelling catheter into blood collection tubes containing sodium heparin. Blood sampling was performed just prior to administration of the third and final dose of drug (0 h) and at 2, 4, 6, 8, 12, and 24 h. Blood samples were centrifuged at 4°C at 1,000 x g for 10 min. Plasma samples were then collected and stored at –80°C until they were shipped for analysis. Skin blister fluid samples (100 to 200 µl in volume) were collected using a 28-gauge needle at simultaneous time points and were stored at –80°C until they were shipped for analysis.
All samples were analyzed by validated reverse phase, high-performance liquid chromatography-tandem mass spectrometry methodology. Due to the limited availability of the blister matrix, an artificial matrix (70% human plasma in normal saline) was used to mimic the study sample composition. As a result, a cross-matrix validation between this proxy matrix and blank blister fluid was undertaken; the recovery of study drug was >90% in both. The lower limits of quantitation for telavancin in human plasma and blister fluid were 250 and 10 ng/ml, respectively. Mean interassay precision (
4.9% coefficient of variation [CV], n = 18) and accuracy (±2.5% deviation of the mean from the theoretical mean [DMT], n = 18) of quality control samples were obtained for plasma over the linear range of 250 to 100,000 ng/ml. Mean interassay precision (5.7% CV, n = 18) and accuracy (±5.5% DMT, n = 18) of quality control samples were obtained for skin blister fluid over the linear range of 10 to 5,000 ng/ml. The overall precision and accuracy of the quality control samples and standards analyzed during the course of the study were better than 15% for all concentrations.
The following pharmacokinetic parameters were estimated by noncompartmental analysis using WinNonlin software (version 3.2; Pharsight Corportation, Mountain View, CA): the maximum concentration of drug in serum and blister fluid (Cmax), the time at which the maximum concentration was reached (Tmax), the area under the curve at steady state (AUCss), the elimination half-life, the clearance, mean residence time, the volume of distribution at steady state (for plasma only), and the Cmin. The penetration of telavancin into blister fluid was determined by comparing the AUC in blister fluid with that in plasma.
Telavancin was well tolerated among the subjects. The most commonly reported adverse events were the presence of dysgeusia (n = 8) and foamy urine (n = 7). The etiology of the foamy urine was most likely due to the excretion of cyclodextrin, a solubilizing agent that is incorporated into the intravenous formulation of telavancin. Both events were mild in intensity and resolved within the study period without any interventions or discontinuations from the study.
The mean concentration-versus-time profile of plasma and blister fluid for the eight subjects who completed the study is illustrated in Fig. 1. The mean pharmacokinetic parameters ± standard deviations found for telavancin in plasma and blister fluid are displayed in Table 1. The peak telavancin level ± standard deviation in plasma was 84.8 ± 5.3 µg/ml, the mean elimination half-life in plasma was 6.26 ± 0.78 h, and the mean AUCss in plasma was 604 ± 83 µg · h/ml. The Tmax in skin blister fluid occurred at 9.3 ± 2.4 h. The mean Cmax of telavancin in blister fluid was 16.0 ± 2.0 µg/ml, the mean elimination half-life in blister fluid was 6.91 ± 0.53 h, and the mean AUCss in blister fluid was 241 ± 33 µg · h/ml. Peak telavancin concentrations in skin blister fluid lagged behind peak concentrations in plasma, but the elimination half-lives remained similar. Telavancin levels were detectable in both plasma and skin blister fluid at all time points. Over the dosing interval, the mean (± standard deviation) ratio of AUCss obtained in blister fluid compared to that in plasma was 40.3% (± 5.8%).
|
|
1 µg/ml for Staphylococcus aureus (including methicillin-resistant S. aureus), 0.125 µg/ml for Streptococcus spp., 1 µg/ml for vancomycin-susceptible Enterococcus spp., and 4 µg/ml for vancomycin-resistant Enterococcus spp. (8, 10). Skin and soft tissue infections are often primarily caused by gram-positive pathogens such as S. aureus, Streptococcus pyogenes, Streptococcus agalactiae, and Enterococcus spp. (1, 2, 6, 11). Telavancin exhibits excellent in vitro activity against these agents. Telavancin is highly protein bound, at approximately 95% (4). Although only total drug concentrations were determined in the current study, Fig. 1 displays both total and estimated free telavancin concentrations in plasma and blister fluid. Estimated free concentrations represent 5% of the total drug concentrations. This is a conservative approach for blister fluid, since protein content and binding ability in this matrix has not been clearly elucidated. Using a S. aureus MIC of 0.5 µg/ml, mean free concentrations of telavancin are above the MICs for approximately 70% and 40% of the dosing intervals for plasma and blister fluid, respectively. In a study by Hedge and colleagues, in which the pharmacodynamics of telavancin was determined in a neutropenic murine thigh infection model, the AUC/MIC ratio was found to be the most predictive parameter describing telavancin's bactericidal activity (4). These authors found that AUC/MIC ratios of approximately 100 for total and 7 for free telavancin concentrations resulted in maximal kill at 24 h. From our current investigation using a S. aureus MIC of 0.5 µg/ml, the derived total and free AUC/MIC ratios are 1,208 and 60.4, respectively, in plasma and 482 and 24.1, respectively, in blister fluid.
This was the first study investigating the penetration of telavancin into skin blister fluid and televancin's pharmacokinetics. Treatment for skin and soft tissue infections can be problematic if the antibiotic does not achieve adequate concentrations at the site of infection. Our study has shown that in both plasma and blister fluid, adequate drug concentrations are achieved that are above the MIC for those pathogens often implicated in skin and soft tissue infections such as S. aureus (including methicillin-resistant S. aureus) and Streptococcus spp. Moreover, AUC/MIC exposures for both total and estimated free concentrations in plasma and blister fluid appear more than adequate to ensure microbiologic eradication. This study is consistent with results from phase II studies indicating telavancin's potential role as a treatment alternative for complicated skin and skin structure infections caused by resistant gram-positive pathogens (12).
|
ACKNOWLEDGMENTS |
|---|
We thank Dana Maglio for her assistance in completing this study.
|
FOOTNOTES |
|---|
|
REFERENCES |
|---|
|
TopAbstractTextReferences |
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |
